1. Skip to header
  2. Skip to main
  3. Skip to content
  4. Skip to sidebar
  5. Skip to footer
  • Home > Blog > Clinical Trial > Clinical Trial Spotlight: Pemetrexed (ALIMTA) Plus Cisplatin for Mesothelioma
Posted on Tuesday, Oct 13, 2009

Clinical Trial Spotlight: Pemetrexed (ALIMTA) Plus Cisplatin for Mesothelioma

Study: Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma

Start Date: January 2009
End Date: January 2020

Recruiting Contacts
Andrea Foster, 416-946-4501 ext 5010, Andrea.Foster@Uhn.on.ca
Jennifer Hornby, BSc CCRP 416-340-4857, Jennifer.Hornby@uhn.on.ca

Information
The University Health Network of Toronto is currently recruiting participants for a clinical trial using a combination of Pemetrexed (Alimta) with Cisplatin prior to surgery followed by radiation therapy after surgery. The goal enrollment for the trial is 45 patients that have been diagnosed with malignant pleural mesothelioma but have not yet undergone treatment.

Previous studies have shown that complete removal of mesothelioma is possible in approximately 30% of the patients, with treatment typically continuing with chemotherapy followed by radiation. The chances of the tumor returning after this trimodal therapy remains high, and the chances of long term survival remains low.

According to the trial information, the combination of Pemetrexed (Alimta) with Cisplatin as chemotherapy treatment is likely to benefit, and potentially cure, a group of patients.

For complete information see ClinicalTrials.